Weight Loss Treatment – Mounjaro 12.5mg – Step 5 – £227.49

What is it?

Mounjaro is a prescription injectable medication intended for self-administration to aid in weight loss. It includes tirzepatide, a peptide that helps control blood sugar and energy levels, which in turn reduces hunger and cravings. By influencing certain brain pathways, it increases the feeling of fullness, helping users stay satisfied for longer. When paired with a healthy diet and consistent exercise, it can result in significant weight loss. Research has demonstrated that it leads to more weight loss than diet and exercise alone.

Who is Mounjaro for?

Ingredients:

Each 12.5 mg dose contains tirzepatide (12.5 mg in 0.6 mL solution), along with sodium phosphate dibasic heptahydrate, sodium chloride, concentrated hydrochloric acid, sodium hydroxide (for pH adjustment), and water for injection.

Administration Guidelines:

Before starting this treatment, make sure to read the instructions for use (IFU) to ensure proper administration. It can be taken at any time of the day, with or without food. The injection can be given in the abdomen, thigh, or upper arm, but remember to alternate the injection sites each time. Always examine the solution before use it should appear clear and colourless or have a slight yellow tint. If the solution is discoloured or has particles, do not use it.

Contraindications:

It is contraindicated in patients with:

• A personal or family history of medullary thyroid carcinoma (MTC) or those with Multiple Endocrine Neoplasia syndrome type 2.
• Known hypersensitivity to tirzepatide or any of its excipients.

Precautions and Warnings:

– Injection Site: The injection should be given in the abdomen, thigh, or upper arm. You can change the injection site and time as needed, without needing to adjust the dosage.

– Missed Dose: If you miss a dose and it’s been no more than 4 days, take the missed dose as soon as you remember and then continue with your next scheduled dose. If more than 4 days have passed, skip the missed dose and resume your normal dosing schedule.

– Change of Injection Day: The day for weekly administration can be adjusted, provided there is a minimum of 3 days between two doses. (≥72 hours).

– Storage: Keep the medication refrigerated (2°C – 8°C) and avoid freezing it. Store it in its original packaging to protect it from light. If needed, it can be kept at room temperature, not exceeding 30°C, for a maximum of 21 days. After this time, dispose of the pre-filled pen.

– Acute Pancreatitis Risk: Caution is advised for patients with a history of pancreatitis. Stop using it if symptoms of pancreatitis occur.

– Hypoglycemia Risk in Type 2 Diabetes: Monitor for hypoglycemia when using Mounjaro in combination with insulin or insulin secretagogues. Dose adjustments of insulin or other medications may be necessary.

– Gastrointestinal Disorders: For patients with severe gastrointestinal conditions, such as gastroparesis, use it with caution.

– Diabetic Retinopathy: Exercise caution in patients with diabetic retinopathy and ensure appropriate monitoring.

– Pregnancy and Lactation: Mounjaro is not advised for use during pregnancy due to a lack of sufficient data. It is also unclear whether the medication passes into breast milk, so the potential risks should be carefully considered to the benefits.

– Effects on Driving and Operating Machinery: It is unlikely to impair the ability to drive or operate machinery, but caution is advised when used with insulin or sulfonylurea to prevent hypoglycemia.

Adverse Effects:

Possible side effects may include, but are not limited to:

– Very Common: Allergic reactions, low blood sugar (especially when used with insulin or sulfonylureas), and dizziness.
– Common: Nausea, diarrhoea, vomiting, constipation, and tiredness.
– Uncommon: Hair thinning, stomach pain, and acute pancreatitis.

For a full list of potential side effects, consult your healthcare provider.

*Note:

• – (1) Dose-dependent
• – (2) More common in certain populations
• – Fatigue may encompass both general exhaustion and physical weakness.